Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor ORIGINAL CONTRIBUTION One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Heikki Joensuu, MD Context Adjuvant imatinib administered for 12 months after surgery has improved Mikael Eriksson, MD recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tu- mor (GIST) compared with placebo. Kirsten Sundby Hall, MD Objective To investigate the role of imatinib administration duration as adjuvant treat- Jo ¨ rg T. Hartmann, MD ment of patients who have a high estimated risk for GIST recurrence after surgery. Daniel Pink, MD Design, Setting, and Patients Patients with KIT-positive GIST removed at sur- Jochen Schu ¨ tte, MD gery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Giuliano Ramadori, MD Sweden. The risk of GIST recurrence was estimated using the modified National In- Peter Hohenberger, MD stitutes of Health Consensus Criteria. Justus Duyster, MD Intervention Imatinib, 400 mg per day, orally for either 12 months or 36 months, Salah-Eddin Al-Batran, MD started within 12 weeks of surgery. Main Outcome Measures The primary end point was RFS; the secondary end points Marcus Schlemmer, MD included overall survival and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/one-vs-three-years-of-adjuvant-imatinib-for-operable-gastrointestinal-5CvcAlZ1ap

References (30)

Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2012.347
pmid
22453568
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Heikki Joensuu, MD Context Adjuvant imatinib administered for 12 months after surgery has improved Mikael Eriksson, MD recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tu- mor (GIST) compared with placebo. Kirsten Sundby Hall, MD Objective To investigate the role of imatinib administration duration as adjuvant treat- Jo ¨ rg T. Hartmann, MD ment of patients who have a high estimated risk for GIST recurrence after surgery. Daniel Pink, MD Design, Setting, and Patients Patients with KIT-positive GIST removed at sur- Jochen Schu ¨ tte, MD gery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Giuliano Ramadori, MD Sweden. The risk of GIST recurrence was estimated using the modified National In- Peter Hohenberger, MD stitutes of Health Consensus Criteria. Justus Duyster, MD Intervention Imatinib, 400 mg per day, orally for either 12 months or 36 months, Salah-Eddin Al-Batran, MD started within 12 weeks of surgery. Main Outcome Measures The primary end point was RFS; the secondary end points Marcus Schlemmer, MD included overall survival and

Journal

JAMAAmerican Medical Association

Published: Mar 28, 2012

There are no references for this article.